Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $484.94, moving +0.67% from the previous trading session.

Ahan Chakraborty headshot

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

by Ahan Chakraborty

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $448.16, signifying a -1.57% move from its prior day's close.

Zacks Market Edge Highlights: Vertex, Zillow RH, Super Micro Computer, Yum China

by Zacks Equity Research

Vertex, Zillow RH, Super Micro Computer, Yum China have been highlighted in this Market Edge article.

Tracey Ryniec headshot

Insider Trades: How to Find the Top Stocks

by Tracey Ryniec

Tracey is joined by Asif Suria, author of The Event-Driven Edge in Investing, to talk about how to get an edge from insider trading.

Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $465.08, denoting a +0.48% change from the preceding trading day.

Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Mark Vickery headshot

Top Analyst Reports for Costco Wholesale, Alibaba & GE Aerospace

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Alibaba Group Holding Limited (BABA) and GE Aerospace (GE), as well as two micro-cap stocks Applied Energetics, Inc. (AERG) and NeurAxis, Inc. (NRXS).

Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?

by Zacks Equity Research

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?

by Kinjel Shah

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $470.78, indicating a -0.07% shift from the previous trading day.

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

by Zacks Equity Research

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor

by Zacks Equity Research

Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Sundeep Ganoria headshot

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

by Sundeep Ganoria

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

Should You Invest in the VanEck Biotech ETF (BBH)?

by Zacks Equity Research

Sector ETF report for BBH

BMY vs. VRTX: Which Stock Is the Better Value Option?

by Zacks Equity Research

BMY vs. VRTX: Which Stock Is the Better Value Option?

Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.

The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna

by Zacks Equity Research

Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.